Can a Urinalysis Detect Cancer?

A standard urinalysis, the kind ordered at a routine checkup, is not designed to diagnose cancer. But it can pick up clues, especially blood in the urine, that sometimes lead to a cancer diagnosis. Beyond that basic test, a growing number of specialized urine-based assays can detect specific cancers with surprisingly good accuracy, and the field is evolving fast. The gap between what a routine urine test can do and what newer urine-based technologies can do is wide enough to be worth understanding clearly.

What a Routine Urinalysis Actually Tells You

A standard urinalysis checks for things like pH, protein, glucose, bacteria, and the presence of blood cells. It is a general health screen, not a cancer test. When your doctor orders one during a physical, they are looking for signs of infection, kidney problems, or diabetes far more often than they are thinking about cancer.

The cancer-relevant finding that a routine urinalysis can flag is hematuria, which is blood in the urine. Sometimes you can see it yourself (the urine looks pink or red), but more often it is microscopic, invisible without a lab test. In a large study of patients with microscopic hematuria, the three-year incidence of urinary tract cancer was under 1%, and the standard definition of microhematuria had only about 50% sensitivity for catching cancer when it was present.¹ In other words, a positive result for blood does not mean cancer is likely, and a negative result does not rule it out. It is a clue, not a conclusion.

Still, hematuria should never be shrugged off. Among patients who present with asymptomatic hematuria and are referred for evaluation, roughly one in five turns out to have bladder cancer, with the odds climbing for older adults, men, and smokers.² That one-in-five figure applies to a selected group already flagged for workup, not to everyone who has a trace of blood on a dipstick. But it illustrates why doctors take hematuria seriously even when there is an obvious benign explanation like a urinary tract infection or vigorous exercise.

Bladder Cancer Has the Most Developed Urine Tests

Because bladder tumors sit directly in the urinary tract, cancer cells and their molecular byproducts shed straight into urine. That makes bladder cancer the most natural target for urine-based detection, and it is the cancer type with the most commercially available urine assays.

Urine cytology, where a pathologist examines urine under a microscope for abnormal-looking cells, has been used for decades. It is extremely specific: if cytology says cancer, it is almost always right. But it misses a lot, with sensitivity around 30% in some studies.³ That means many people with bladder cancer will get a clean cytology result.

Several FDA-approved molecular tests aim to do better. NMP22 BladderChek, which measures a protein released by dying bladder cells, has pooled sensitivity around 56% and specificity around 88% across studies.⁴ Other FDA-cleared options include UroVysion (a fluorescence test that looks for chromosomal abnormalities) and BTA (bladder tumor antigen) tests.⁵ None of these replace cystoscopy, the gold standard where a tiny camera is threaded into the bladder, but they can help clinicians decide who needs that invasive procedure and how closely to monitor patients after treatment.

Newer urine-based assays still in development or recently entering clinical use have shown pooled sensitivity up to 90% and specificity up to 92%, significantly outperforming cytology.⁶ If those numbers hold up in broader practice, they could meaningfully reduce how often patients need a camera in their bladder.

False Positives and What Throws Off the Results

One of the practical headaches with urine cancer tests is that the very conditions that prompt testing can muddy the results. NMP22, for instance, is sensitive to blood and inflammation in the urine. When researchers added increasing amounts of blood to urine samples from healthy people, NMP22 levels rose to the point where they mimicked cancer readings.⁷ Since hematuria is often the reason a patient gets tested in the first place, this creates a frustrating circular problem.

Urinary tract instrumentation, such as catheterization or a recent cystoscopy, also inflates NMP22 false-positive rates dramatically. In one study, false positives jumped to about 74% in patients who had recently undergone instrumentation, compared with about 38% in those who had not. Inflammation pushed the false-positive rate even higher. Cytology, immunocytology, and FISH-based tests were far more resistant to these confounders.⁸ The lesson for patients is straightforward: if you have an active infection, recently had a catheter, or have visible blood in your urine, some biomarker tests are less reliable, and your doctor should factor that in when interpreting results.

Prostate Cancer and Urine Tests

Prostate cancer is the most common cancer in men, and PSA blood testing has long been the front-line screening tool. But PSA is notoriously imprecise, flagging many men who turn out not to have clinically significant disease and missing some who do. Urine-based tests are emerging as a way to add precision, particularly when the question is whether a biopsy is actually necessary.

The ExoDx Prostate test, also known as the EPI test, analyzes tiny vesicles (exosomes) shed by prostate cells into urine. In a study of men with a prior negative biopsy who were being considered for a repeat biopsy, the test showed a negative predictive value of 92%, meaning that when it scored low, the chance of missing high-grade cancer was small. Using the test’s cutoff could have avoided roughly a quarter of all biopsies in that group.⁹ The MyProstateScore test, which analyzes urine collected after a digital rectal exam, has also shown strong performance for distinguishing clinically significant prostate cancer from low-risk disease.¹⁰

A cost-effectiveness analysis estimated that incorporating a urinary biomarker panel into the prostate biopsy decision could save roughly $1,700 per patient over an 18-year time horizon while slightly improving health outcomes, primarily by sparing men from unnecessary biopsies and the complications that follow.¹¹ These tests are not screening tools meant for everyone; they are triage tools used after an elevated PSA or a suspicious finding to sharpen the decision about what to do next.

Urine-Based HPV Testing for Cervical Cancer

Cervical cancer screening traditionally requires a clinician-collected cervical sample. That is a barrier for many people, whether because of discomfort, access to healthcare, or cultural reasons. Researchers have been investigating whether testing urine for human papillomavirus (HPV) could serve as an alternative.

A UK diagnostic study found that urine HPV testing achieved 96% sensitivity for detecting high-grade cervical changes and about 85% specificity, performing close to the cervical swab it was compared against.¹² A separate study in women referred for colposcopy reported somewhat lower sensitivity for urine at about 87% but higher specificity than the cervical sample in that setting.¹³ An umbrella review pooling data across multiple meta-analyses found combined sensitivity around 78% to 87% depending on how the sample was collected and which HPV types were targeted.¹⁴

The appeal here is obvious: a urine sample is something anyone can provide at home without a clinic visit. If these tests can reliably catch the HPV infections that cause cervical cancer, they could reach people who currently skip screening altogether. The evidence is encouraging, though sensitivity varies enough across studies that the test is not yet a standard replacement for clinician-collected samples in most guidelines.

Can Urine Detect Cancers Outside the Urinary Tract?

This is the frontier that surprises most people. Cancers of the lung, stomach, breast, and other distant organs also leave molecular traces in urine, carried there through the bloodstream. Tumor DNA enters the blood, gets filtered by the kidneys, and ends up as short fragments in urine. This transrenal cell-free DNA is extremely small, often shorter than 50 base pairs, but modern sequencing technology can detect it.¹⁵

Urinary cell-free DNA carries genetic information from cells shedding directly into the urinary tract as well as fragments that traveled from distant tumors through circulation.¹⁶ Researchers have used this to look for mutations associated with colorectal cancer, lung cancer, and head-and-neck cancers in urine samples. The concept also extends to proteins. Mass spectrometry of urine has identified hundreds of proteins that differ between gastric cancer patients and healthy controls, opening the door to possible diagnostic panels for cancers that have nothing to do with the kidneys or bladder.¹⁷ Urine-based protein profiling has already yielded disease-associated biomarkers not only for kidney and bladder conditions but also for diseases affecting organs far from the urinary tract.¹⁸

None of these distant-organ urine tests are ready for routine clinical use yet. But the research makes clear that the old assumption, “urine can only tell you about urinary tract problems,” is outdated.

DNA Methylation and Epigenetic Markers

Cancer cells often have distinctive patterns of DNA methylation, a chemical modification that changes how genes are switched on or off. These patterns show up in DNA fragments shed into urine and can be measured without a biopsy.

For bladder cancer, a panel of three methylation markers achieved 97% specificity and 87% sensitivity in a validation cohort of over 200 samples.¹⁹ Those numbers are competitive with or better than many existing bladder biomarker tests, and methylation panels have the advantage of being highly specific to cancer biology rather than picking up signals from infection or inflammation. Bladder cancer proteomics panels have shown similar promise, with one 13-protein model reaching about 91% sensitivity and 73% specificity for distinguishing cancer from non-cancer samples.²⁰

These molecular approaches are part of a broader shift toward multi-marker panels, where combining several signals from a single urine sample can catch cancers more reliably than any single test. The more markers you layer together, the harder it becomes for a cancer to slip through all of them undetected.

MicroRNA Profiling and Exosomes

Tiny vesicles called exosomes, released by cells throughout the body, end up in urine carrying cargo that reflects the cell they came from. Among that cargo are microRNAs, short stretches of RNA that regulate gene activity. Different cancers produce different microRNA signatures, and researchers have been mining urinary exosomes for diagnostic patterns.

In prostate cancer, one study identified a specific microRNA (miR-532-5p) in urinary exosomes that predicted biochemical recurrence, an early sign of disease returning after treatment.²¹ For lung cancer, a nanowire-based extraction platform captured urinary exosomes and used machine learning to identify microRNA profiles that distinguished early-stage lung cancer patients from healthy controls with an area-under-the-curve of 0.99, an exceptionally high mark.²² About 2,500 species of microRNA were confirmed present in urine, meaning the raw material for detecting many different cancers is already there, waiting for the right analytical tools.

The practical challenge is moving from proof-of-concept studies with small sample sizes into large-scale validation. Promising lab numbers do not always survive contact with the messiness of real-world patient populations, varying hydration levels, timing of collection, and coexisting conditions.

Volatile Compounds and Biological Sensors

Cancers alter metabolism, and some of those metabolic changes produce volatile organic compounds (VOCs) that end up in urine and can be smelled or sensed. A review of 44 studies covering cancer-related VOCs in urine found promising results across multiple cancer types using mass spectrometry and electronic nose devices, though the field is still working toward standardized methods.²³

One of the more unusual lines of research uses the nematode C. elegans, a tiny worm with a remarkably sensitive olfactory system. These worms are attracted to urine from cancer patients and repelled by urine from healthy individuals. A commercial test called N-NOSE, already available in Japan, claims to screen for 15 cancer types with about 88% sensitivity and 90% specificity in early-stage disease.²⁴ Early-stage prostate cancer urine also attracts the worms in a dilution-dependent manner, suggesting the signal is concentration-related rather than binary.²⁵ The concept has even been extended to detect cancer in dogs.²⁶

Whether a worm-based test will ever become standard medical practice outside of Japan remains to be seen. But the underlying principle, that cancers produce a detectable chemical signature in urine, is well supported and is being pursued through multiple technological approaches simultaneously.

What Happens After an Abnormal Finding

Finding something suspicious on a urine test does not mean you have cancer. It means you need further evaluation, and guidelines spell out what that looks like. The American Urological Association’s microhematuria guidelines stratify patients into low, intermediate, and high risk for urinary tract malignancy based on age, sex, smoking history, degree of blood in the urine, and other factors.²⁷ Low-risk patients may only need a repeat urinalysis. Intermediate-risk patients might get an ultrasound. High-risk patients are typically referred for cystoscopy and cross-sectional imaging.

Validation studies have examined whether ultrasound is sufficient for low and intermediate-risk patients, as the updated AUA guidelines recommend, rather than subjecting everyone to a CT scan.²⁸ The goal is to avoid both extremes: ignoring blood in the urine (since some of those patients do have cancer) and overtesting everyone with expensive, radiation-heavy imaging when only a small fraction have anything serious. Research has shown that high-risk patients with hematuria are sometimes not evaluated according to guideline recommendations, which can delay diagnosis.²⁹

Why Compliance Matters More Than the Test Itself

Bladder cancer monitoring after initial treatment is a long, expensive process. Patients need repeated cystoscopies, sometimes for years. The procedure is uncomfortable, and compliance tends to drop over time. This is one of the strongest practical arguments for urine-based tests: not that they are perfect, but that people will actually do them. A urine sample is painless, cheap, and requires no appointment with a specialist. Even a modestly accurate test that patients actually complete on schedule can catch recurrences that a perfect test missed because the patient skipped their appointment.³⁰

Health economic modeling supports this logic beyond bladder cancer. Liquid biopsy approaches, including urine-based tests, appear cost-effective for screening and early detection across several cancer types compared with doing nothing, and in some scenarios they produce outright cost savings when factoring in the downstream expenses of late-stage cancer treatment.³¹

Smartphone-Readable Point-of-Care Tests

The most futuristic branch of urine cancer testing involves devices you could use at home. One system recently demonstrated in a double-blind study used buoyant fluorescent particles mixed with unprocessed urine to detect bladder cancer biomarkers. A smartphone camera read the fluorescence change, and the system distinguished cancerous samples, including early-stage disease, with about 90% accuracy across 105 participants.³² No lab processing, no centrifuge, no specialized equipment beyond a phone.

Whether such tests become consumer products, clinic tools, or both depends on regulatory approval and large-scale validation studies still to come. But the trajectory is clear: urine cancer testing is moving from centralized laboratories toward something faster, cheaper, and closer to the patient. The raw biological information is already in the sample. The question now is building tools reliable enough to read it outside a research setting.